Aurinia Pharmaceuticals (AUPH) Capital Leases (2023 - 2026)

Aurinia Pharmaceuticals has reported Capital Leases for 4 years, with the latest figure at $48.2 million in Q1 2026.

• For the quarter ending Q1 2026, Capital Leases fell 15.22% year-over-year to $48.2 million; the trailing twelve-month figure through Mar 2026 stood at $48.2 million (down 15.22% YoY), and the FY2025 full-year result was $52.3 million, down 10.64% from the prior year.
• Capital Leases for Q1 2026 stood at $48.2 million, down from $52.3 million in the prior quarter.
• The five-year high for Capital Leases was $79.4 million in Q2 2023, with the low at $48.2 million in Q1 2026.
• Historically, Capital Leases has averaged $63.0 million across 4 years, with a median of $62.1 million in 2024.
• The largest YoY upside for Capital Leases was 8.64% in 2024 against a maximum downside of 22.42% in 2024.
• Aurinia Pharmaceuticals' Capital Leases stood at $75.5 million in 2023, then decreased by 22.42% to $58.6 million in 2024, then slipped by 10.64% to $52.3 million in 2025, then declined by 7.91% to $48.2 million in 2026.
• The last three Capital Leases figures came in at $48.2 million (Q1 2026), $52.3 million (Q4 2025), and $55.7 million (Q3 2025), per Business Quant data.